Disc Medicine, Inc.

Disc Medicine, Inc., listed on Nasdaq under the ticker GMTX, filed its Form 10-K annual report with the SEC on March 29, 2021, covering fiscal year 2020. The company is a clinical-stage biopharmaceutical firm concentrated on developing therapies for serious hematologic diseases, placing it squarely within the life sciences and rare disease sector. The 10-K reflects the company's operating status as a publicly traded entity following its transition from earlier corporate predecessors active in the biotech space. Disc Medicine represents a segment of post-transaction biopharma companies that SPAC-focused investors routinely track for pipeline updates and capital activity. For complete filing history, deal structure details, and real-time monitoring on GMTX, sign up for full data access at SpacDesk.